Altimmune, Inc. (ALT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Altimmune, Inc. reported revenue of $41.0K, up 105.0% from the prior year. The company ran a net loss, with a net margin of -214861.0%. It held $279.93M in total assets against $55.04M in total liabilities.
Key ratios (FY2025)
-230461.0%
Operating margin
-214861.0%
Net margin
-39.2%
Return on equity
+105.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | -$68.0K | $4.41M | — | — | — | — | — |
| Operating Income | -$94.49M | -$103.17M | -$95.93M | -$87.74M | -$96.91M | -$54.80M | -$21.46M | -$42.83M | -$52.05M | -$11.09M |
| Net Income | -$88.09M | -$95.06M | -$88.45M | -$84.71M | -$97.09M | -$49.04M | -$20.52M | -$39.17M | -$46.43M | -$11.09M |
| EPS (Diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | — | — | — | $2.95 |
| Total Assets | $279.93M | $139.31M | $210.64M | $206.93M | $218.87M | $245.12M | $54.06M | $54.75M | $63.03M | $38.40M |
| Total Liabilities | $55.04M | $15.80M | $16.54M | $21.64M | $19.73M | $19.24M | $8.54M | $6.44M | $14.35M | $6.19M |
| Shareholders' Equity | $224.89M | $123.51M | $194.10M | $185.29M | $199.13M | $225.88M | $45.52M | $48.31M | $39.40M | $32.21M |
| Cash & Equivalents | $43.76M | $36.93M | $135.12M | $111.10M | $190.30M | $115.92M | $8.96M | $33.72M | $8.77M | $2.88M |
| Operating Cash Flow | -$67.53M | -$79.85M | -$75.81M | -$62.59M | -$78.24M | -$34.31M | -$9.60M | -$9.39M | -$20.21M | — |
| Capital Expenditures | $11.0K | — | $47.0K | $126.0K | $12.12M | $204.0K | $1.2K | $975.4K | $112.4K | $125.0K |
| Shares Outstanding | 110.88M | 72.35M | 70.68M | 49.20M | 40.99M | 37.14M | 15.31M | 9.08M | 608.5K | 6.92M |